<DOC>
	<DOCNO>NCT00623415</DOCNO>
	<brief_summary>Flupirtine , non-opioid analgesic drug , show additional neuroprotective function , give twice daily oral medication patient relapse remit multiple sclerosis period 12 month . Neuroprotection assess magnetic resonance imaging , magnetic resonance spectroscopy , optical coherence tomography , clinical examination .</brief_summary>
	<brief_title>Flupirtine Oral Treatment Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<mesh_term>Flupirtine</mesh_term>
	<criteria>Relapsingremitting MS accord revise McDonaldCriteria ( 2005 ) EDSS ≤ 4.0 Stable treatment Interferonβ1b least 6 month Sufficient birth control ( PearlIndex &lt; 1 ) Any MScourse RRMS Clinically relevant gastrointestinal disease Clinically relevant pulmonary , cardiological , infectious CNSdisease Clinically relevant disease liver bile system , pathological value transaminase , gammaGT bilirubin . Hepatitis ( except uncomplicated hepatitis A complete remission Clinically relevant dysfunction kidney ( creatinine &gt; 180 µmol/l ) bone marrow ( HB &lt; 8.5 g/dl , WBC &lt; 2.5/nl thrombocyte &lt; 125/nl ) Myasthenia gravis Oral anticoagulation ( phenprocoumon ) Treatment carbamazepine paracetamol Drug alcohol abuse Pregnancy lactation period Treatment time study complete lymphoradiation , monoclonal antibody ( e.g . antiCD4 , Campath 1H , natalizumab ) , mitoxantrone , cyclophosphamide , cyclosporin , azathioprine Treatment within 6 month randomization immunomodulatory substance interferonβ1b intravenous methylprednisolone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>